Skip to main content
. Author manuscript; available in PMC: 2017 Sep 22.
Published in final edited form as: Sci Transl Med. 2017 Mar 22;9(382):eaaf9194. doi: 10.1126/scitranslmed.aaf9194

Figure 3. MIV-09 inhibits type I IFN.

Figure 3

(A) moDCs were treated with increasing doses of Influenza vaccines used during the 2006–2007, 2008–2009, 2009–2010 and 2010–2011 seasons. The graph summarizes data from seven donors. (B) moDCs were treated with 25 μL/mL TIV-09 combined with increasing doses of MIV-09 for 8h. Supernatants were harvested for ELISA. The graph summarizes data from seven donors. (C) moDCs were activated with TIV-09 (6 μL/mL), LPS (50 ng/mL), CD40L (1 μg/mL), R848 (3 μg/mL), or CL097 (5 μg/mL) alone or with MIV-09 (10 μL/mL) with or without recombinant IFN-α (2000 U/mL). Supernatant cytokine concentrations were assessed by Luminex. The graph summarizes data from seven donors. (D) moDCs were stimulated with TIV-09, LPS, CD40L, R848 or CL097 with or without MIV-09. The surface expression of moDC activation markers was examined by flow cytometry. The figure is representative of experiments in four independent donors. (E) Ingenuity Pathway Analysis of the transcripts unique to each vaccine and most highly expressed after vaccine exposure. The top three canonical pathways enriched in the transcripts induced by each vaccine are shown (N=3). (Mann-Whitney test; *: p<0.05; **: p<0.01; ***: p<0.001).